Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 30, 2025 | June 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 30, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 10,629 |
Reported balance
After 2025-05-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-30 · Grant · Acquired 4,800 · Balance 10,629 F1: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2035-05-30 | Direct | 16,000 |
Reported balance
After 2025-05-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-30 · Grant · Acquired 16,000 · Balance 16,000 F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
F2: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.
F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2025 Filed Jun 2, 2025 16:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 16,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0000950170-25-080309 · ownership.xml · derivative · entry 2 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-30 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 16:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080309 · ownership.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,629 F1 · shares: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:24 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionOptions to purchase common stock · Derivative | 1,667 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073710 · ownership.xml · derivative · entry 2 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2024-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. F2 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:24 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionCommon Stock, par value $0.0001 per share | 1,667 | $30.00 | $50,010.00 |
DisclosureSEC source: 0000950170-24-073710 · ownership.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:27 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068009 · ownership.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,162 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 2,783 unvested RSUs that were granted on May 30, 2024 and will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 16:56 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 2,783 | $0.00 Strike: $45.92 | $0.00 |
DisclosureSEC source: 0001209191-24-005673 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 18:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionOptions to purchase common stock · Derivative | 629 | $4.97 Strike: $4.97 | $3,126.13 |
DisclosureSEC source: 0001209191-24-002449 · doc4.xml · derivative · entry 2 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 629 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option vested in equal monthly installments over a period of 12 months commencing on February 28, 2014. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 18:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionCommon Stock | 629 | $4.97 | $3,126.13 |
DisclosureSEC source: 0001209191-24-002449 · doc4.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 22, 2023 16:22 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-23-031453 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document |
| May 18, 2022 Filed May 19, 2022 14:38 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 79,600 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-22-030446 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,600 Underlying: Common Stock · 79,600 shares Expires 2032-05-18 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:41 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041459 · doc4.xml · derivative · entry 2 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 16:41 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041459 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031662 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 22, 2019 Filed Jun 28, 2019 16:04 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 33,300 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001209191-19-039465 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 33,300 shares Expires 2029-05-22 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 24, 2018 Filed May 29, 2018 16:09 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 34,000 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001209191-18-033772 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-05-24 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:37 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 30,500 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001209191-17-035850 · doc4.xml · derivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2027-05-25 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 11, 2017 Filed May 12, 2017 11:45 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 500 | $6.23 | $3,115.00 |
DisclosureSEC source: 0001209191-17-031765 · doc4.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 14:42 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,000 | $7.49 | $7,490.00 |
DisclosureSEC source: 0001209191-16-151671 · doc4.xml · nonDerivative · entry 1 HOLMER ALAN F · CIK 0001329585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.